Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-3.42 | N/A | -758.96% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-3.42 | N/A | -758.96% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns over the current financial performance. They highlighted a commitment to addressing operational challenges moving forward.
Management acknowledged the challenges faced in the quarter.
They emphasized ongoing efforts to improve operational efficiency.
This earnings report indicates significant challenges for United Therapeutics, particularly with a large EPS miss. Despite this, the stock saw a slight increase of 0.40%, which may reflect investor optimism about future recovery efforts. The lack of revenue data and guidance adds uncertainty to the outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AGILENT TECHNOLOGIES
Feb 17, 2009